Background and Purpose-The present study examined the contributions of a rise in cGMP versus a fall in 20-HETE levels to the vasodilator response to nitric oxide (NO) in the cerebral circulation of the rat. Methods-Intact rat middle cerebral and basilar arteries were bathed in physiological saline solution containing indomethacin (5 mol/L) and baicalein (0.5 mol/L) and pressurized at 90 mm Hg. Relaxations to sodium nitroprusside (SNP) were studied before and after addition of [1H-[1,2,4]oxadiazole[4,3-a]quinoxalin-1-one] (ODQ, a guanylyl cyclase blocker), 8R,9S,11S-(Ϫ)-9-methoxy-carbamyl-8-methyl-2,3,9,10-tetrahydro-8,11-epoxy-1H,8H,11H-2,7b,11a-trizadibenzo-(a,g)-cycloocta-(c,d,e)-trinden-1-one (KT5823, a protein kinase G blocker), and 20-hydroxyeicosatetraenoic acid (20-HETE). Cerebral blood flow was measured by using a laser Doppler flow probe over a thin cranial window in anesthetized rats, and the effects of intracerebroventricular infusion of 1-hexamine,6-(2-hydroxy-1-methyl-2-nitrosohydrazino)N-methyl (MAHMA nonoate) and dibromododecenyl methylsulfimide (DDMS) were determined. Results-SNP-induced dilation of serotonin-preconstricted (0.2 mol/L) middle cerebral arteries (10 Ϫ7 to 10 Ϫ3 mol/L) was attenuated in arteries treated with ODQ (10 mol/L) or KT5823 (1 mol/L) by 52% and 27%, respectively. Preventing the NO-induced fall in intracellular 20-HETE, by adding 20-HETE (100 nmol/L) to the bath, reduced the dilation to SNP by 62%. Simultaneous administration of ODQ and 20-HETE markedly attenuated the SNP-induced dilation by 90%. In basilar arteries, ODQ (10 mol/L) alone completely blocked the response to SNP. Infusion of MAHMA nonoate (10 nmol/min ICV) in anesthetized rats increased cerebral blood flow by 52% before and 8% after blockade of the endogenous production of 20-HETE with DDMS (50 pmol/min). Conclusions-These results suggest that NO dilates cerebral arteries through both cGMP-dependent and cGMPindependent pathways and that inhibition of 20-HETE formation contributes to the cerebral vasodilator response to NO both in vitro and in vivo.
R ecent studies indicate that nitric oxide (NO) plays a central role in the regulation of cerebral blood flow (CBF). [1] [2] [3] [4] [5] [6] [7] [8] [9] In this regard, the finding that inhibitors of NO synthase lower CBF indicates that the tonic release of NO plays an important role in the regulation of basal cerebral vascular tone. 3, 4 NO also mediates the cerebral vascular responses to a wide variety of stimuli. For example, endothelium-derived NO contributes to the vasodilator responses to acetylcholine, substance P, bradykinin, and ␣ 2 -adrenergic receptor agonists. [5] [6] [7] There is also evidence that NO contributes to the rise in CBF produced by hypercapnia (5% CO 2 ) 3,4,6,9 and inhalational anesthetics. 10, 11 Moreover, several studies have indicated that inhibitors of NO synthase attenuate the changes in CBF in response to electrical stimulation, 12 seizures, 6 and nociceptive stimulation. 13 These results suggest that NO couples CBF to changes in neuronal activity.
See Editorial Comment, page 2734
The vasodilator actions of NO in the cerebral circulation are generally thought to be due to the stimulation of guanylyl cyclase (GC), as has been reported for the aorta and large conduit arteries. 2, 14 NO and cGMP activate Ca 2ϩ -activated K ϩ channels in vascular smooth muscle cells from a variety of vascular beds. [15] [16] [17] [18] Activation of these channels hyperpolarizes vascular smooth muscle and limits Ca 2ϩ influx through voltage-gated channels. 2 In the cerebral circulation, several pharmacological and patch-clamp studies have been performed to directly examine the mechanism by which NO alters cerebral vascular tone. Recent studies reporting that inhibitors of GC attenuate the dilator response to NO in pial arterioles in vivo 19 -21 support a primary role for cGMP in mediating the vasodilator response to NO. On the other hand, the results of other studies indicating that NO can still dilate cerebral arteries and large conduit arteries treated with inhibitors of GC in vitro suggest that other mechanisms may also be involved. 2, 18, [22] [23] [24] [25] We have recently reported that NO donors inhibit enzymes of the cytochrome P-450 4A (CYP 4A) family that catalyze the formation of the vasoconstrictor 20-hydroxyeicosatetraenoic acid (20-HETE) in renal arterioles. 26, 27 Cerebral arteries also express mRNA and protein for the CYP 4A2 enzyme and produce 20-HETE when incubated with arachidonic acid. 28 20-HETE is a potent vasoconstrictor of cerebral arteries that inhibits Ca 2ϩ -activated K ϩ channels. 28, 29 Given our recent findings that inhibition of the formation of 20-HETE contributes to the vasodilator response to NO in renal arterioles, 26, 27 the purpose of the present study was (1) to evaluate the relative contribution of cGMP-dependent and cGMPindependent pathways to the vasodilator actions of NO in cerebral arteries and (2) to examine whether inhibition of the formation of the vasoconstrictor 20-HETE mediates the cGMP-independent actions of NO in cerebral arteries both in vitro and in vivo.
Materials and Methods
Adult male Sprague-Dawley rats (10 to 12 weeks old) were purchased from Harlan Sprague-Dawley Laboratories (Indianapolis, Ind). The rats were housed in the animal care facility at the Medical College of Wisconsin, which is approved by the American Association for the Accreditation of Laboratory Animal Care. The animals had free access to food and water. All protocols involving animals received approval by the Animal Care Committee of the Medical College of Wisconsin.
Isolated MCA and BA Studies
Rats were anesthetized with sodium pentobarbital (50 mg/kg body wt IP). The brain was removed, and small branches of middle cerebral artery (MCA, inner diameter Ͻ65 m) or basilar artery (BA, inner diameter Ͼ140 m) were microdissected and mounted on glass micropipettes in a perfusion chamber containing physiological saline solution equilibrated with a 95% O 2 /5% CO 2 gas mixture and maintained at 37°C. The inflow pipette was connected to a pressurized reservoir to allow for control of intraluminal perfusion pressure, which was monitored by use of a transducer (Cobe). The outflow cannula was clamped off, and intraluminal pressure was maintained at 90 mm Hg during the experiment. The composition of the perfusate and the bath was (mmol/L) NaCl 119, KCl 4.7, MgSO 4 1.17, CaCl 2 1.6, NaHCO 3 12, NaH 2 PO 4 1.18, EDTA 0.03, and glucose 10, pH 7.4. Vascular diameters were measured by using a video system composed of a stereo microscope (Carl Zeiss, Inc), a CCTV television camera (model KP-130AU, Hitachi), a videocassette recorder (model AG-7300, Panasonic), a television monitor (model CVM-1271, Sony), and a video measuring system (model VIA-100, Boeckeler Instrument Co). Indomethacin (5 mol/L) and baicalein (0.5 mol/L) were added to the bath to block the endogenous metabolism of arachidonic acid via the cyclooxygenase and lipoxygenase pathways, as we have previously described. 26 
Measurement of NO Concentration
The concentration of NO generated in the bath solution by various doses of sodium nitroprusside (SNP) was measured with a 2-mmdiameter gas-permeant membrane NO sensor (Iso-NOP) and a NO meter (World Precision Instruments). The meter was calibrated by chemically reducing known amounts of NO 2 to NO in the presence of KI and H 2 SO 4 . SNP (10 Ϫ5 to 10 Ϫ3 mol/L) was added to the bath containing physiological salt solution saturated with 95% O 2 /5% CO 2 at 37°C, and the NO concentration was recorded 3 minutes after addition of the NO donor.
Relative Contribution of cGMP-Dependent and -Independent Pathways to Vasodilator Actions of NO in Cerebral Arteries
To determine whether the cGMP pathway mediates the dilator actions of NO, the response to SNP (10 Ϫ7 to 10 Ϫ3 mol/L) was examined in MCAs and BAs preconstricted with serotonin (0.2 mol/L) before and after blocking GC with [1H- [1, 2, 4] oxadiazole [4,3-a] quinoxalin-1-one] (ODQ, 10 mol/L) or cGMP-dependent protein kinase (PKG) with 8R,9S,11S-(Ϫ)-9-methoxy-carbamyl-8-methyl-2,3,9,10-tetrahydro-8,11-epoxy-1H,8H,11H-2,7b,11a-trizadibenzo-(a,g)-cycloocta-(c,d,e)-trinden-1-one (KT5823, 1 mol/L). Vascular diameter was measured 3 minutes after the addition of each dose of SNP to the bath. The effectiveness of blockade of PKG with KT5823 was assessed by comparing the vasodilator response to 8-bromo-cGMP (10 Ϫ4 mol/L) before and after addition of KT5823 to the bath.
To examine whether inhibition of the formation of the vasoconstrictor 20-HETE contributes to the cGMP-independent actions of NO in cerebral arteries, the response to SNP (10 Ϫ7 to 10 Ϫ3 mol/L) was examined in MCAs preconstricted with serotonin (0.2 mol/L) before and after fixing 20-HETE levels at 100 nmol/L by adding exogenous 20-HETE to the bath. Vascular diameter was measured 3 minutes after the addition of each dose of SNP to the bath.
To examine whether the effects of ODQ were specific to NO donors, we studied the effects of ODQ on the vascular response to the NO-independent dilator adenosine. Cumulative concentrationresponse curves to adenosine (10 Ϫ7 to 10 Ϫ3 mol/L) were obtained in MCAs preconstricted with serotonin (0.2 mol/L) under control conditions and after blockade of GC with ODQ (10 mol/L).
To determine whether different mechanisms mediate the NOinduced vasodilation in large versus small cerebral vessels, we compared the vascular responses of BAs and MCAs to the stable cell-permeable cGMP analogue 8-bromo-cGMP. Cumulative doseresponse curves to 8-bromo-cGMP (10 Ϫ8 to 10 Ϫ4 mol/L) were generated in these arteries after 30 minutes of incubation with indomethacin (5 mol/L) and baicalein (0.5 mol/L) to block the endogenous metabolism of arachidonic acid via the cyclooxygenase and lipoxygenase pathways. Vascular diameter was measured 2 minutes after the addition of each dose of 8-bromo-cGMP to the bath.
To examine whether the effects of dibromododecenyl methylsulfimide (DDMS) were specific to NO donors, we studied the effects of DDMS on the vascular response to the NO-independent vasodilator adenosine. Cumulative concentration-response curves to adenosine (10 Ϫ7 to 10 Ϫ3 mol/L) were obtained in MCAs preconstricted with serotonin (0.2 mol/L) under control conditions and after blockade of 20-HETE synthesis with DDMS (25 mol/L).
Western Blot Analysis of Soluble GC and CYP 4A Proteins
To determine whether differences in the expression of soluble GC (sGC) or CYP 4A proteins in large versus small cerebral vessels may explain the differences in the NO-induced responses in MCAs and BAs, we compared the levels of GC and CYP 4A protein in these arteries. MCAs and BAs were microdissected from the brain of 5 Sprague-Dawley rats. The vessels were homogenized in a 10 mmol/L potassium phosphate buffer at pH 7.7 containing 250 mmol/L sucrose, 1 mmol/L EDTA, 2 mol/L leupeptin, 1 mol/L pepstatin, 2 g/mL aprotinin, and 0.1 mol/L phenylmethylsulfonyl fluoride. Microsomes prepared from liver of Sprague-Dawley rats were used as a positive control. Protein concentrations were measured by the Bradford method (Bio-Rad) with bovine serum albumin used as a standard. Sample protein (2 g) was subjected to 7.5% SDS-polyacrylamide gel electrophoresis on 8ϫ10-cm gels at 100 V for 1 hour. The separated proteins were transferred electrophoretically to polyvinylidene fluoride membranes at 100 V for 1 hour. After transfer, nonspecific binding was blocked by incubating the membranes overnight at 4°C in TBS-T buffer (6 mmol/L Tris-HCl, 4 mmol/L Tris-base, 150 mmol/L NaCl, and 0.08% Tween 20, pH 7.5) containing 10% nonfat dry milk. The next day, the membranes were washed 4 times with TBS-T and subsequently incubated for 2 hours with a polyclonal antibody raised against the ␣ 1 and ␤ 1 subunits of sGC (Cayman Chemical) at a 1:5000 dilution in TBS-T buffer containing 2% milk or a polyclonal antibody raised against rat CYP 4A1 (Gentest Corp), which crossreacts with CYP 4A2 and 4A3, at a 1:5000 dilution. After incubation with the primary antibody, the membranes were washed 6 times with TBS-T buffer and incubated with either goat anti-rabbit IgG conjugated with alkaline phosphatase for the sGC (Santa Cruz Biotechnology) at a 1:5000 dilution or anti-goat IgG conjugated with alkaline phosphatase (Bio-Rad) at a 1:5000 dilution in 2% milk for 1 hour for the CYP 4A. After 6 more washes, the immunoblots were developed by using Vistra ECF substrate (Amersham), and the conversion of the substrate to a fluorescent product by the alkaline phosphatase-coupled second antibody was captured by use of a FluorImager scanner (Molecular Dynamics).
Measurement of CBF In Vivo
To determine whether inhibition of the formation of the vasoconstrictor 20-HETE contributes to the NO-induced vasodilation in vivo, we measured the effects of an intracerebroventricular infusion of the short-acting NO donor 1-hexamine,6-(2-hydroxy-1-methyl-2-nitrosohydrazino)N-methyl (MAHMA nonoate) on CBF in anesthetized rats before and after blockade of 20-HETE formation with DDMS. Experiments were performed in 7 male rats anesthetized with ketamine (70 mg/kg IM) and a low dose of pentobarbital (10 mg/kg IP) and in 3 rats anesthetized with chloralose (60 mg/kg IP) and urethane (400 mg/kg IP) followed by a constant intravenous infusion of chloralose alone (50 mg/kg per hour). The rats were tracheostomized, paralyzed with gallamine triethiodide (80 mg/kg IP), and artificially ventilated with a small animal ventilator (model SAR-830, CWE) with 30% O 2 in N 2 . Cannulas were placed in the femoral artery for measurement of arterial pressure and in the jugular vein for intravenous infusions. Expired PO 2 and PCO 2 were measured with a gas analyzer, and the ventilation rate was controlled to maintain constant PCO 2 . CBF was measured at 2 to 4 different sites by use of a laser Doppler flowmeter (Oxford Optronix, Inc), as we have previously described in detail. 9 Briefly, the head of the rat was placed in a stereotaxic apparatus, and the bone covering the right parietal cranium was thinned by using a low-speed air drill until a thin translucent cranial window remained. A laser Doppler flow (LDF) probe was positioned over the thin cranial window, and a 30-gauge cannula was inserted into the left lateral ventricle for intracerebroventricular infusions. After surgery, a 1-hour equilibration period was allowed. The LDF response to intracerebroventricular infusion of the short-acting NO donor MAHMA nonoate (10 nmol/min) was measured during a control period and after 30 minutes of blocking 20-HETE production with a constant intracerebroventricular infusion of the selective CYP 4A inhibitor DDMS (50 pmol/min). Results are expressed as a percent change from the baseline value measured at each site and then averaged to a single value per rat.
Drugs and Chemicals
All chemicals were of analytical grade. Indomethacin, sodium nitroprusside, serotonin, adenosine, 8-bromo-cGMP, leupeptin, pepstatin, aprotinin, and phenylmethylsulfonyl fluoride were purchased from Sigma Chemical Co. MAHMA nonoate was purchased from Cayman Chemical. ODQ was purchased from Alexis Co. Baicalein and KT5823 were obtained from Biomol. DDMS and 20-HETE were synthesized by Dr J.R. Falck (Southwestern Medical Center, Dallas, Tex).
Statistics
Values are expressed as meanϮSEM. Statistical differences in mean values within and between groups were examined by ANOVA for repeated measures followed by the Duncan multiple range test. A value of PϽ0.05 was considered significant.
Results

Role of cGMP in Mediating the Dilator Response to NO in MCAs
A schematic figure summarizing the effects of various agonists and antagonists used in our studies is presented in Figure  1 . The long-acting NO donor SNP was used in the isolatedvessel studies because it produces a steady release of NO that lasts for 30 minutes. The short-acting NO donor MAHMA nonoate was used in the CBF studies because it has a half-life of only 2 to 3 minutes, and its vasodilator effects are readily reversed. ODQ was used to inhibit sGC activity. KT5823 was used to block PKG. The formation of 20-HETE in cerebral arteries in vivo was blocked with DDMS, a selective competitive inhibitor of 20-HETE synthesis. 30 The NO-induced fall in 20-HETE formation was prevented by adding exogenous 20-HETE (100 nmol/L) to the bath.
The contribution of cGMP to the vasodilator response to NO was assessed by comparing the concentration-dependent response to SNP under control conditions and after blocking GC with ODQ. The results of these studies are summarized in Figure 2A . The baseline inner diameter of these arteries measured at 90 mm Hg averaged 63Ϯ3 m (nϭ6 vessels, 5 rats). Serotonin (0.2 mol/L) reduced vessel diameter by 52Ϯ3%, and SNP (10 Ϫ7 to 10 Ϫ3 mol/L) dose-dependently increased vessel diameter to a maximum of 89Ϯ6% of the serotonin-constricted value. The concentration of NO generated averaged 25Ϯ2, 40Ϯ5, and 139Ϯ29 nmol/L at 3 minutes after addition of 10
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, and 10 Ϫ3 mol/L SNP to the bath. Blockade of GC with ODQ (10 mol/L) reduced the basal diameter of serotonin-preconstricted arteries by 15Ϯ6%, and it attenuated the vasodilator response to all doses of SNP by Ϸ50%.
To determine whether ODQ had any nonspecific inhibitory effects, the effects of ODQ on the response to the NOindependent dilator adenosine were examined in MCAs. The inner diameter of these MCAs measured at 90 mm Hg averaged 77Ϯ5 m (nϭ3 vessels, 3 rats), and it fell to 43Ϯ3% of control after adding serotonin to the bath. Under control conditions, adenosine (10 Ϫ7 to 10 Ϫ3 mol/L) dosedependently increased vessel diameter to a maximum of 92Ϯ2% of the serotonin-constricted value. Blockade of GC with ODQ (10 mol/L) did not impair the vasodilator response to adenosine. After ODQ, adenosine (10 Ϫ7 to 10 Ϫ3 mol/L) dose-dependently increased vessel diameter to a maximum of 92Ϯ4% of the serotonin-constricted value. The effects of blocking PKG with KT5823 on the vasodilator response to SNP in MCAs are summarized in Figure 2B . The baseline inner diameters of these arteries averaged 64Ϯ2 m (nϭ5 vessels, 4 rats), and it fell to 51Ϯ2% of control after adding serotonin to the bath. Under control conditions, SNP (10 Ϫ7 to 10 Ϫ3 mol/L) dose-dependently increased vessel diameter to a maximum of 103Ϯ2% of the serotonin-constricted value. Blockade of PKG activity with KT5823 (1 mol/L) reduced the response to SNP by 27Ϯ9%. The effectiveness of the blockade of PKG activity was assessed by comparing the vasodilator response to 8-bromocGMP before and after adding KT5823 to the bath. In serotonin-preconstricted cerebral arteries, addition of 10 Ϫ4 mol/L 8-bromo-cGMP increased vascular diameter to 88Ϯ3% of the serotonin-constricted value ( Figure 2B, inset) , and KT5823 (1 mol/L) completely blocked the vasodilator response to 8-bromo-cGMP in these vessels.
Role of 20-HETE in Mediating the Dilator Response to NO in MCAs
The contribution of a fall in 20-HETE levels to the dilator response to NO in cerebral arterioles was evaluated by comparing the response to SNP under control conditions and after preventing the fall in endogenous 20-HETE levels produced by the NO donor. This was achieved by adding a high concentration of exogenous 20-HETE (100 nmol/L) to the bath. The results of these experiments are summarized in Figure 3 . The control inner diameter of these vessels averaged 63Ϯ3 m (nϭ6 vessels, 5 rats), and it fell to 51Ϯ2% of control after adding serotonin to the bath. Under these conditions, SNP (10 Ϫ7 to 10 Ϫ3 mol/L) dose-dependently dilated these arteries to a maximum of 92Ϯ2% of the serotonin-constricted value. 20-HETE had no significant effect on the baseline diameter of these preconstricted vessels. However, it did reduce the vasodilator response to SNP by Ϸ63%. In the presence of 100 nmol/L 20-HETE, SNP dose-dependently dilated these arteries to a maximum of 34Ϯ5% of the serotonin-constricted value. Simultaneous blockade of both pathways by adding ODQ and 20-HETE to the bath completely abolished the vasodilator response to SNP (Figure 3) . The control inner diameter of these vessels averaged 63Ϯ4 m (nϭ6 vessels, 5 rats), and it fell to 50Ϯ3% of control after adding serotonin to the bath. Under these conditions, SNP (10 Ϫ7 to 10 Ϫ3 mol/L) dose-dependently dilated these arteries to a maximum of 97Ϯ5% of the serotonin-constricted value. However, in the presence of 20-HETE (100 nmol/L) and ODQ (10 mol/L), vessel diameter increased only by 8Ϯ3% from the serotoninconstricted value in response to the highest dose of SNP (10 Ϫ3 mol/L). 
Role of cGMP in Mediating the Dilator Response to NO in BAs
The relative contribution of the cGMP pathway to the vasodilator responses to NO in larger cerebral arteries was also assessed. The results of these experiments are summarized in Figure 4 . The control inner diameter of the BAs studied averaged 147Ϯ12 m (nϭ4 vessels, 4 rats), and it fell to 46Ϯ4% after adding serotonin (0.2 mol/L) to the bath. SNP (10 Ϫ7 to 10 Ϫ3 mol/L) dose-dependently dilated these arteries to a maximum of 64Ϯ4% of the serotoninpreconstricted diameter. Blocking GC with ODQ completely eliminated the vasodilator response to SNP in BAs. Vessel diameter increased only to a maximum of 2Ϯ0.2% in response to the highest dose of the NO donor.
cGMP Sensitivity in MCAs and BAs
To determine the mechanisms underlying the difference in the importance of the cGMP pathway to the vasodilator response to NO in BAs versus MCAs, we compared cumulative dose-response curves to 8-bromo-cGMP (10 Ϫ8 to 10 Ϫ4 mol/L) in MCAs and BAs in the presence of indomethacin (5 mol/L) and baicalein (0.5 mol/L). The results of these studies are presented in Figure 5 . The dilator response to cGMP after preconstriction with serotonin was similar in BAs versus MCAs except at the lowest concentration of agonist studied. The control inner diameter of BAs averaged 154Ϯ10 m (nϭ5 vessels, 5 rats). 8-Bromo-cGMP (10 Ϫ8 to 10 Ϫ4 mol/L) dose-dependently dilated BAs to a maximum of 66Ϯ8% and MCAs to a maximum of 70Ϯ4%.
Immunodetection of CYP 4A and sGC Proteins in MCAs and BAs
We also examined whether differences in the expression of CYP 4A and sGC could explain the difference in the relative contribution of the cGMP pathway to the NO-mediated vasodilation in BAs versus MCAs. Typical examples of immunoblots for CYP 4A and sGC are presented in Figure 6 . Only one CYP 4A immunoreactive band (Ϸ52 kDa) was detected in both MCAs and BAs, and it migrated like the CYP 4A2 and 4A3 isoforms expressed in the positive control (rat liver). There was no significant difference in the levels of CYP 4A protein in MCAs and BAs. We also performed immunoblot experiments for sGC using a polyclonal antibody. Liver, MCAs, and BAs exhibited one sGC immunoreactive band (Ϸ77 kDa), and there was no significant difference in pixel density between bands, suggesting that they express similar levels of sGC protein.
Contribution of 20-HETE to the CBF Response to NO Donors in the Intact Rat
To determine whether inhibition of 20-HETE production contributes to the dilator actions of NO in the cerebral circulation of rats in vivo, we examined the effects of an intracerebroventricular infusion of the CYP 4A inhibitor DDMS (50 pmol/min) on the CBF response to an intracere- Immunoblots of sGC were detected by use of a polyclonal antibody that cross-reacts with the ␣ and ␤ subunits of the enzyme. Microsomes prepared from rat liver were used as positive control for both proteins.
broventricular infusion of the short-acting NO donor MAHMA nonoate (10 nmol/min) in anesthetized rats. The results of these studies are presented in Figure 7 . In preliminary experiments, we found that 10 nmol/min was the largest dose of NO donor that could be infused intracerebroventricularly that did not lower systemic blood pressure. The responses to NO donor and DDMS were similar in ketamine pentobarbital-anesthetized rats compared with chloralosetreated rats; thus, the results from these 2 groups were combined. In the present experiments, mean arterial pressure averaged 106Ϯ5 mm Hg during intracerebroventricular infusion of MAHMA nonoate and 104Ϯ4 mm Hg during intracerebroventricular infusion of the NO donor and DDMS (nϭ10 rats). Cerebral LDF signal increased by 52Ϯ6% during intracerebroventricular infusion of the NO donor. After blockade of 20-HETE formation with DDMS (50 pmol/min), the NO donor increased the cerebral LDF signal by only 8Ϯ2%. In time-control experiments (nϭ4 rats), intracerebroventricular infusion of vehicle alone had no effect on the second response to intracerebroventricular infusion of the NO donor (data not shown). To determine whether DDMS had nonspecific inhibitory effects on cerebral vascular responses, the effects of DDMS on the response to the NO-independent vasodilator adenosine were examined in isolated arteries. The inner diameter of MCAs averaged 77Ϯ7 m (nϭ4 vessels, 3 rats), and it fell to 42Ϯ5% of control after adding serotonin to the bath. Under these conditions, adenosine (10 Ϫ7 to 10 Ϫ3 mol/L) dosedependently increased vessel diameter to a maximum of 91Ϯ7% of the serotonin-constricted value. Blockade of 20-HETE formation with DDMS (25 mol/L) did not impair the vasodilator response to adenosine. After DDMS, adenosine (10 Ϫ7 to 10 Ϫ3 mol/L) dose-dependently increased vessel diameter to a maximum of 99Ϯ9% of the serotoninpreconstricted diameter.
Discussion
Although NO plays an important role in the control of cerebrovascular tone, its mechanism of action is still not completely understood. It is generally thought that the effects of NO in the cerebral circulation are due to stimulation of GC, followed by a rise in cGMP levels and activation of K ϩ channels. 2,14,19 -21,31 However, the results of several recent studies showing that inhibitors of GC cannot completely prevent NO-induced vasodilation in arteries from different vascular beds, including cerebral vessels, suggest that a "cGMP-independent" mechanism may also be involved. 2, 18, [22] [23] [24] [25] 32 Therefore, the present study examined the relative contributions of the cGMP-dependent and -independent pathway to the NO-induced vasodilation of rat cerebral arteries. We found that in small lenticulostriate branches of MCAs, blockade of GC with ODQ attenuated the vasodilator response to NO donors by only Ϸ50%. In contrast, ODQ had no effect on the vasodilator response to adenosine, suggesting that the effects of ODQ were selective for the NO donor. Similarly, blockade of PKG with KT5823 decreased the response to NO by only Ϸ25%. The inability of KT5823 to block the response to SNP was not due to a failure to inhibit PKG activity. Indeed, KT5823 completely blocked the vasodilator response to 8-bromo-cGMP in these vessels. Together, the results suggest that in rat MCAs studied in vitro, a large component, between 50% and 75%, of the response to NO is cGMP independent.
We have recently reported that NO inhibits the CYP 4A enzyme responsible for the formation of 20-HETE in the kidney and that a fall in 20-HETE levels mediates the cGMP-independent actions of NO in the renal microcirculation. 26, 27 These findings led us to consider the hypothesis that a similar mechanism may contribute to the vasodilator response to NO in the cerebral microcirculation. Our results indicate that preventing the NO-induced fall in 20-HETE levels markedly impairs the vasodilator response to low doses of SNP and attenuates the response to higher doses of SNP by Ϸ65% in MCAs. Simultaneous addition of 20-HETE (100 nmol/L) and ODQ to the bath completely blocks the vasodilator response to SNP in these arteries. Moreover, the residual dilator response to the NO donor seen after fixing 20-HETE levels was blocked by ODQ, indicating that it is mediated by cGMP. These findings suggest that the vasodilator response to NO in MCAs of the rat can be completely explained on the basis of a rise in cGMP and a fall in 20-HETE levels and that the direct effect of NO on K ϩ channels does not contribute to this response.
Our findings in MCAs are not consistent with the results of recent studies demonstrating that GC inhibition blocks 80% to 90% of the vasodilator response to NO donors in rat, 19 mouse, 20 or rabbit 21 pial arterioles and rat BAs 33 in vivo. We considered the possibility that different mechanisms may mediate the NO-induced vasodilation in different types of cerebral vessels. Indeed, our findings in BAs are entirely consistent with the results of the previous studies showing that blockade of GC completely impaired the dilator response to NO donors in pial and BAs in vivo and large conduit arteries in vitro. 2, 14, 21, 31, 33 At the present time, we cannot explain why the relative contribution of the cGMP pathway to the NO-mediated vasodilation differs in BAs versus MCAs. One possible explanation could be that the expression of GC and CYP 4A enzymes might differ in BAs and MCAs. However, our immunoblot results do not support this idea. We found that the expression of sGC and CYP 4A protein is similar in rat MCAs and BAs. It is also possible that the response of K ϩ channels and other proteins to cGMP and/or 20-HETE may differ in BAs versus MCAs. However, in the present study, both BAs and MCAs exhibited a similar sensitivity to exogenous administration of 8-bromo-cGMP. It is also possible that NO donors may activate different types of K ϩ channels in BAs versus MCAs. In this regard, Sobey and Faraci 33 reported that vasodilatation caused by NO in rat BAs is mediated by activation of voltage-dependent K ϩ channels through a cGMP-dependent pathway. In contrast, studies by Onoue and Katusic 17 indicate that in canine MCAs, most of the NO-induced vasodilation is cGMP independent and is mediated by activation of large-conductance Ca 2ϩ -activated K ϩ channels. The conclusion that the NO-induced vasodilation of cerebral vessels is cGMP-dependent is based on the evidence that ODQ is a selective inhibitor of sGC. Recently, Feelisch et al 25 reported that ODQ inhibits not only sGC but also NO synthase and markedly attenuates the release of NO from SNP and glycerol trinitrate by tissue. These side effects of ODQ may explain why this inhibitor appears to be more effective at blocking the vasodilator response to SNP and NO-dependent vasodilators in vivo compared with in vitro preparations. Studies showing that ODQ completely blocks NO-induced vasodilation were performed by using SNP and cranial window preparations in vivo, 19 -21,33 whereas the studies showing incomplete blockade of NO responses by ODQ were performed by using isolated vessel preparations. 18, 22, 25 The surrounding parenchymal tissue in experimental in vivo preparations catalytically releases large quantities of NO from SNP and other donors, whereas the spontaneous hydrolysis of these donors in aqueous solutions used in vitro is limited. Thus, the nonspecific effects of ODQ would be more pronounced in studies using cranial window preparations. Regardless of the mechanisms involved, the present in vitro studies demonstrate that a fall in 20-HETE levels contributes in a major way to the vasodilator response to NO in the MCA of the rat but not in the larger BA.
Additional studies were performed to determine to what extent, if any, changes in 20-HETE levels that occur in some but not all cerebral arteries contribute to the CBF response to NO in the intact rat. We measured CBF through a thin cranial window by use of laser Doppler flowmetry to obtain an idea of the integrated blood flow effects of NO on cerebral vessels of various sizes. We found that an intracerebroventricular infusion of the NO donor increased CBF by Ϸ50%. After blockade of 20-HETE formation with DDMS, the NO donor increased CBF by only Ϸ8%. These results indicate that blockade of the formation of 20-HETE attenuated the cerebral vasodilator response to NO by Ϸ80%. Because CYP 4A activity can be affected by anesthetics, we performed our experiments with 2 different anesthetics, ie, ketamine and a low dose of pentobarbital or chloralose and urethane. We found that DDMS attenuated the cerebral vasodilator response to the NO donor by about the same degree regardless of the anesthetic used. The reason the blockade of 20-HETE formation had such a large effect on the cerebral vasodilator response to NO in vivo remains to be determined, but it may indicate that an intracerebroventricular infusion of the NO donor could preferentially affect the small resistance vessels in the cerebral cortex.
In summary, the present results indicate that in the rat BA, nearly all of the vasodilator response to NO can be blocked by ODQ; thus, it is cGMP dependent. In rat MCA, however, about half of the dilator response to NO is cGMP independent, and this is largely mediated by a NO-induced fall in 20-HETE production. Moreover, the results of our in vivo studies indicate that inhibition of the formation of 20-HETE does contribute to the cerebral vasodilator response to NO in the intact rat.
Editorial Comment
The mechanisms of regulation of cerebral vascular tone are complex. Multiple vasodilator and vasoconstrictor agents are involved. There is a strong possibility that these agents may interact with each other. A fuller understanding of the mechanisms of regulation of the cerebral circulation requires a more complete understanding of the mechanisms by which vasoactive agents exert their action and also a more detailed understanding of the mechanisms by which they interact with each other.
The article above by Alonso-Galicia and colleagues addresses the mechanisms by which NO dilates cerebral arteries. The authors showed that two mechanisms are involved. First, NO activates guanylyl cyclase to generate cyclic GMP. The second mechanism involves the inhibition by NO of the synthesis of 20-HETE, a vasoconstrictor agent. The authors showed that both of these mechanisms are involved in vitro and in vivo. Another important finding was that the relative contributions of the two mechanisms were different in different cerebral arteries. For example, in the basilar artery the vasodilator action of NO was due mostly to guanylyl cyclase activation, while in the middle cerebral arteries both mechanisms contributed. It is likely that differences between vessels as well as species differences may be uncovered by future investigation. Studies such as this emphasize that the great complexity of the mechanisms of regulation of vascular tone is a fertile field of investigation.
